Clinical Trials
18 trialsNCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06707896 2025-06-25
TCR1020-CD8 T Cells in KRAS-mutated Cancers
University of Pennsylvania
Phase 1 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT03802747 2024-12-09
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Phase 1 Withdrawn
NCT06216561 2024-08-20
Intraperitoneal LSTA1 in CRS-HIPEC
University of California, San Diego
Phase 1 Withdrawn
NCT04054752 2023-11-02
Vaccine Response With NT-I7
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT04632199 2022-08-24
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
Ipsen
Phase 1 Withdrawn
NCT03682744 2022-04-06
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT01273402 2021-08-16
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 1 Withdrawn
NCT03380689 2021-03-08
SIRB2
Fujian Cancer Hospital
Phase 1 Withdrawn
NCT04195373 2020-11-25
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Themis Bioscience GmbH
Phase 1 Withdrawn
NCT03644459 2020-03-11
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
Lynkcell Inc.
Phase 1 Withdrawn
NCT00005030 2018-11-14
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02630420 2017-10-26
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Yale University
Phase 1 Withdrawn
NCT02573220 2016-12-09
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
University of Chicago
Phase 1 Withdrawn
NCT00960427 2013-04-16
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00025532 2012-09-14
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT00780988 2012-01-24
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Stanford University
Phase 1 Withdrawn